Key clinical point: For patients with acute exacerbations of chronic obstructive pulmonary disease, point-of-care C-reactive protein testing reduced antibiotic use with no evidence of harm.
Major finding: Antibiotic use was reported by fewer patients in the CRP testing group, compared with the usual-care group (57.0% vs. 77.4%; adjusted odds ratio, 0.31, 95% confidence interval 0.20-0.47).
Study details: Results of the PACE study, a randomized, controlled trial including more than 600 patients presenting to UK primary care practices with acute exacerbations of COPD.
Disclosures: The Health Technology Assessment Program of the UK National Institute for Health Research supported the study. The lead study author reported disclosures related to Roche Molecular Systems and Roche Molecular Diagnostics, among others.
Butler CC et al. N Engl J Med. 2019 Jul 10;381:111-20. doi: 10.1056/NEJMoa1803185.